The amniotic membrane as a source of stem cells

Carmen L. Insausti, Miguel Blanquer, Patricia Bleda, Paqui Iniesta, María J. Majado, Gregorio Castellanos and José M. Moraleda

Hematology Department, Cellular Therapy Unit, University Hospital Virgen de la Arrixaca, Ctra Madrid-Cartagena, El Palmar, Murcia, Spain.

Offprint requests to: Prof. José M. Moraleda, Servicio de Hematología y Hemoterapia, Unidad de Terapia Celular, Hospital Virgen de la Arrixaca, Ctra. Madrid-Cartagena, 30120 El Palmar, Murcia, Spain. e-mail: jmoraled@um.es


Summary. Cellular therapy has emerged as a new potential tool for curing a wide range of degenerative diseases and tissue necrosis. Embryonic stem cells possess potential for differentiation into a wide range of cell lineages, but the ethical issues associated with establishment of this human cell line have to be resolved prior to any use. The bone marrow (BM) is the usual source of adult stem cells for hematopoietic stem cell transplants and cellular therapy, but the BM harvest is a surgical procedure that requires general anesthesia or sedation, and there seems to be a reduction of the proliferative potential and differentiation capacity of the marrow mesenchymal stem cells in older donors. For these reasons there is an increasing interest in other sources of stem cells from adult and fetal tissues. The amniotic membrane (AM) or amnion is a tissue of particular interest because its cells possess characteristics of stem cells with multipotent differentiation ability, and because of low immunogenicity and easy procurement from the placenta, which is a discarded tissue after parturition, thus avoiding the current controversies associated with the use of human embryonic stem cells. Therefore, amniotic membrane has been proposed as a good candidate to be used in cellular therapy and regenerative medicine. Histol Histopathol 25, 91-98 (2010)

Key words: Amnion, Stem cell, Amniotic epithelial stem cell, Amniotic mesenchymal stem cell, Differentiation

DOI: 10.14670/HH-25.91